MANNEDORF, SWITZERLAND--(Marketwire - October 12, 2010) -
Tecan Group AG /
Tecan Group and Luminex Corporation Partner to Develop Automated Newborn
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.
New solution combines multiplexing and automation technologies to create
novel system that provides faster results and saves valuable time and
resources in newborn screening laboratories
Männedorf, Switzerland, and Austin, Texas - October 12, 2010 - The Tecan
Group (SWISS: TECN) and Luminex Corporation (NASDAQ: LMNX) have announced
that they will collaborate on the development of a new automated newborn
screening solution that will provide faster results for infants' potential
health concerns. The companies have entered into a global OEM agreement
that allows them to combine Luminex® xMAP® technology and LX 200™
instrument with Tecan's flexible and reliable Freedom EVO® liquid
handling platform and HydroFlex™ washer. The new automated newborn
screening solution will help laboratories enhance efficiency, save vital
resources and analyze more samples more quickly. Luminex expects to launch
the automated newborn screening solution in 2011.
Thomas Bachmann, CEO of Tecan, said: "We are delighted that we have been
chosen by Luminex to supply a fully automated solution for such an
important application. This global OEM agreement is building on a long,
well established partnership of creating the most advanced automated
solutions in the research market for Luminex xMAP technology."
Luminex xMAP technology enables large numbers of biological tests to be
conducted simultaneously and analyzed quickly, cost-effectively and
accurately. Once it receives regulatory clearance, NeoPlex4™ will be a
fully automated, walk-away testing platform for multiplexed newborn
screening. These high-volume screening assays test newborn infants for
several different biomarkers linked to critical diseases. Each of these
conditions can cause severe mental and physical disability if untreated. If
detected early through testing, effective treatment can be initiated.
Multiplexing these tests together from one sample offers significant
improvements in testing efficiency.
Patrick Balthrop, CEO of Luminex, said: "Automation continues to be a top
priority for Luminex and our customers. The high testing volumes in the
newborn screening market require full sample-to-answer automation for the
thousands of specimens processed by each customer per day. We evaluated
several different robotic solutions to achieve this full automation for our
xMAP technology and determined that Tecan was the best option available for
this application. We have had a very effective relationship with Tecan and
we are proud to be partnered with them in this effort."
Tecan (www.tecan.com) is a leading global provider of laboratory
instruments and solutions in biopharmaceuticals, forensics, and clinical
diagnostics. The company specializes in the development, production and
distribution of instruments and automated workflow solutions for
laboratories in the life sciences sector. Its clients include
pharmaceutical and biotechnology companies, university research
departments, forensic and diagnostic laboratories. As an original equipment
manufacturer, Tecan is also a leader in developing and manufacturing OEM
instruments and components that are then distributed by partner companies.
Founded in Switzerland in 1980, the company has manufacturing, research and
development sites in both Europe and North America and maintains a sales
and service network in 52 countries. In 2009, Tecan generated sales of CHF
392 million (USD 361.2 million; EUR 259.6 million). Registered shares of
Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters:
TECZn.S/ ISIN CH0012100191).
About Luminex Corporation
Luminex Corporation develops, manufactures and markets proprietary
biological testing technologies with applications throughout the diagnostic
and life sciences industries. The Company's xMAP® multiplex solutions
include an open- architecture, multi-analyte technology platform that
delivers fast, accurate and cost-effective bioassay results to markets as
diverse as pharmaceutical drug discovery, clinical diagnostics and
biomedical research, including the genomics and proteomics markets. The
Company's xMAP Technology is sold worldwide and is already in use in
leading clinical laboratories as well as major pharmaceutical, diagnostic
and biotechnology companies. Further information on Luminex Corporation or
xMAP Technology can be obtained at www.luminexcorp.com.
For further information:
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
Luminex Corporate Contact:
Harriss T. Currie
Vice President, Finance and Chief Financial Officer
Sr. Director Investor Relations
Luminex Media Contact:
--- End of Message ---
Tecan Group AG
Seestrasse 103 Männedorf Switzerland
Press Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Tecan Group AG via Thomson Reuters ONE